{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:23:48Z","timestamp":1793924628294,"version":"4.8.0"},"reference-count":125,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Kidney fibrosis, diffused into the interstitium, vessels, and glomerulus, is the main pathologic feature associated with loss of renal function and chronic kidney disease (CKD). Fibrosis may be triggered in kidney diseases by different genetic and molecular insults. However, several studies have shown that fibrosis can be linked to oxidative stress and mitochondrial dysfunction in CKD. In this review, we will focus on three pathways that link oxidative stress and kidney fibrosis, namely: (i) hyperglycemia and mitochondrial energy imbalance, (ii) the mineralocorticoid signaling pathway, and (iii) the hypoxia-inducible factor (HIF) pathway. We selected these pathways because they are targeted by available medications capable of reducing kidney fibrosis, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and HIF-1alpha-prolyl hydroxylase inhibitors. These drugs have shown a reduction in oxidative stress in the kidney and a reduced collagen deposition across different CKD subtypes. However, there is still a long and winding road to a clear understanding of the anti-fibrotic effects of these compounds in humans, due to the inherent practical and ethical difficulties in obtaining sequential kidney biopsies and the lack of specific fibrosis biomarkers measurable in easily accessible matrices like urine. In this narrative review, we will describe these three pathways, their interconnections, and their link to and activity in oxidative stress and kidney fibrosis.<\/jats:p>","DOI":"10.3390\/biom14010137","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T11:36:41Z","timestamp":1705923401000},"page":"137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities"],"prefix":"10.3390","volume":"14","author":[{"given":"Francesco","family":"Patera","sequence":"first","affiliation":[{"name":"Division of Nephrology, Azienda Ospedaliera di Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-7840","authenticated-orcid":false,"given":"Leonardo","family":"Gatticchi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-9288","authenticated-orcid":false,"given":"Barbara","family":"Cellini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Chiasserini","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-0702","authenticated-orcid":false,"given":"Gianpaolo","family":"Reboldi","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Azienda Ospedaliera di Perugia, 06132 Perugia, Italy"},{"name":"Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: An update 2022","volume":"12","author":"Kovesdy","year":"2022","journal-title":"Kidney Int. Suppl."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O\u2019Callaghan, C.A., Lasserson, D.S., and Hobbs, F.D. (2016). Global Prevalence of Chronic Kidney Disease\u2014A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158765"},{"key":"ref_3","unstructured":"Center of Disease Control (2023, October 31). Chronic Kidney Disease in the United States, Available online: https:\/\/www.cdc.gov\/kidneydisease\/pdf\/CKD-Factsheet-H.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.kint.2021.11.028","article-title":"Thirty years of the International Banff Classification for Allograft Pathology: The past, present, and future of kidney transplant diagnostics","volume":"101","author":"Loupy","year":"2022","journal-title":"Kidney Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40620-022-01545-0","article-title":"Correction to: Semiquantitative classification (SQC) and Oxford classifications predict poor renal outcome better than The International Study of Kidney Disease in Children (ISKDC) and Haas in patients with IgAV nephritis: A multicenter study","volume":"36","author":"Kifer","year":"2023","journal-title":"J. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fphar.2017.00520","article-title":"Progression of Tubulointerstitial Fibrosis and the Chronic Kidney Disease Phenotype\u2014Role of Risk Factors and Epigenetics","volume":"8","author":"Hewitson","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Haaskjold, Y.L., Bjorneklett, R., Bostad, L., Bostad, L.S., Lura, N.G., and Knoop, T. (2022). Utilizing the MEST score for prognostic staging in IgA nephropathy. BMC Nephrol., 23.","DOI":"10.1186\/s12882-021-02653-y"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: Clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJM199811123392007","article-title":"Pathophysiology of progressive nephropathies","volume":"339","author":"Remuzzi","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Duni, A., Liakopoulos, V., Roumeliotis, S., Peschos, D., and Dounousi, E. (2019). Oxidative Stress in the Pathogenesis and Evolution of Chronic Kidney Disease: Untangling Ariadne\u2019s Thread. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153711"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biocel.2017.09.009","article-title":"FGF23 activates injury-primed renal fibroblasts via FGFR4-dependent signalling and enhancement of TGF-beta autoinduction","volume":"92","author":"Smith","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41598-017-02709-w","article-title":"FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts","volume":"7","author":"Smith","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1096\/fj.201900893R","article-title":"Klotho regulation by albuminuria is dependent on ATF3 and endoplasmic reticulum stress","volume":"34","author":"Delitsikou","year":"2020","journal-title":"FASEB J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/ndt\/gfx376","article-title":"Albumin downregulates Klotho in tubular cells","volume":"33","author":"Izquierdo","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Fujii, W., and Shibata, S. (2023). Mineralocorticoid Receptor Antagonists for Preventing Chronic Kidney Disease Progression: Current Evidence and Future Challenges. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097719"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 102, S1\u2013S127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"De Nicola, L., Gabbai, F.B., Garofalo, C., Conte, G., and Minutolo, R. (2020). Nephroprotection by SGLT2 Inhibition: Back to the Future?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072243"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.kint.2017.12.026","article-title":"Drug repurposing in kidney disease","volume":"94","author":"Panchapakesan","year":"2018","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/14656566.2018.1551362","article-title":"Preventing and treating kidney disease in patients with type 2 diabetes","volume":"20","author":"Delanaye","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Podkowinska, A., and Formanowicz, D. (2020). Chronic Kidney Disease as Oxidative Stress- and Inflammatory-Mediated Cardiovascular Disease. Antioxidants, 9.","DOI":"10.3390\/antiox9080752"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5114\/ms.2022.117714","article-title":"Oxidative stress mechanisms as potential therapeutic targets in chronic kidney disease","volume":"38","author":"Dobrek","year":"2022","journal-title":"Med. Stud. Stud. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Uddin, M.J., Kim, E.H., Hannan, M.A., and Ha, H. (2021). Pharmacotherapy against Oxidative Stress in Chronic Kidney Disease: Promising Small Molecule Natural Products Targeting Nrf2-HO-1 Signaling. Antioxidants, 10.","DOI":"10.3390\/antiox10020258"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e165654","DOI":"10.1172\/JCI165654","article-title":"Molecular pathways that drive diabetic kidney disease","volume":"133","author":"Mohandes","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1084\/jem.20081188","article-title":"Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia","volume":"205","author":"Brasacchio","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_27","first-page":"E3002","article-title":"Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT\/EDIC type 1 diabetes cohort","volume":"113","author":"Chen","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/ki.2011.39","article-title":"Histone deacetylase inhibition attenuates diabetes-associated kidney growth: Potential role for epigenetic modification of the epidermal growth factor receptor","volume":"79","author":"Gilbert","year":"2011","journal-title":"Kidney Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ahmad, M., Abramovich, I., Agranovich, B., Nemirovski, A., Gottlieb, E., Hinden, L., and Tam, J. (2022). Kidney Proximal Tubule GLUT2-More than Meets the Eye. Cells, 12.","DOI":"10.3390\/cells12010094"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Granata, S., Zaza, G., Simone, S., Villani, G., Latorre, D., Pontrelli, P., Carella, M., Schena, F.P., Grandaliano, G., and Pertosa, G. (2009). Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genom., 10.","DOI":"10.1186\/1471-2164-10-388"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"F941","DOI":"10.1152\/ajprenal.00203.2019","article-title":"Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice","volume":"317","author":"Lanaspa","year":"2019","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.tcb.2022.03.012","article-title":"The multifaceted role of kidney tubule mitochondrial dysfunction in kidney disease development","volume":"32","author":"Doke","year":"2022","journal-title":"Trends Cell Biol."},{"key":"ref_33","first-page":"F407","article-title":"Metabolic substrate utilization by rabbit proximal tubule. An NADH fluorescence study","volume":"254","author":"Balaban","year":"1988","journal-title":"Am. J. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e139826","DOI":"10.1172\/jci.insight.139826","article-title":"Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease","volume":"6","author":"Thome","year":"2020","journal-title":"JCI Insight"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1681\/ASN.2017020130","article-title":"PGC-1\u03b1 Protects from Notch-Induced Kidney Fibrosis Development","volume":"28","author":"Han","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e140695","DOI":"10.1172\/JCI140695","article-title":"Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis","volume":"131","author":"Miguel","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1681\/ASN.2017030314","article-title":"Kidney Proximal Tubule Lipoapoptosis Is Regulated by Fatty Acid Transporter-2 (FATP2)","volume":"29","author":"Khan","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e136845","DOI":"10.1172\/jci.insight.136845","article-title":"Fatty acid transport protein-2 regulates glycemic control and diabetic kidney disease progression","volume":"5","author":"Khan","year":"2020","journal-title":"JCI Insight"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/s41419-020-03199-x","article-title":"Involvement of FATP2-mediated tubular lipid metabolic reprogramming in renal fibrogenesis","volume":"11","author":"Chen","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2337\/diab.44.2.234","article-title":"Inhibition of sorbitol dehydrogenase. Effects on vascular and neural dysfunction in streptozocin-induced diabetic rats","volume":"44","author":"Tilton","year":"1995","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/cbf.1358","article-title":"Hexosamine induction of oxidative stress, hypertrophy and laminin expression in renal mesangial cells: Effect of the anti-oxidant alpha-lipoic acid","volume":"25","author":"Singh","year":"2007","journal-title":"Cell Biochem. Funct."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"106326","DOI":"10.1016\/j.phrs.2022.106326","article-title":"Polyol pathway and redox balance in diabetes","volume":"182","author":"Garg","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2146512","DOI":"10.1080\/0886022X.2022.2146512","article-title":"Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention","volume":"45","author":"Ma","year":"2023","journal-title":"Ren. Fail."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kang, Q., and Yang, C. (2020). Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol., 37.","DOI":"10.1016\/j.redox.2020.101799"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7950457","DOI":"10.1155\/2020\/7950457","article-title":"WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling","volume":"2020","author":"Zhou","year":"2020","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s001250051142","article-title":"Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-kappaB","volume":"42","author":"Hofmann","year":"1999","journal-title":"Diabetologia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3892\/ijmm.2017.3098","article-title":"Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2\/STAT3 pathway activation","volume":"40","author":"Yu","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MNH.0000000000000489","article-title":"Nonproteinuric progressive diabetic kidney disease","volume":"28","author":"Zoccali","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"118855","DOI":"10.1016\/j.lfs.2020.118855","article-title":"Sinomenine improve diabetic nephropathy by inhibiting fibrosis and regulating the JAK2\/STAT3\/SOCS1 pathway in streptozotocin-induced diabetic rats","volume":"265","author":"Zhu","year":"2021","journal-title":"Life Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.bbrc.2016.07.115","article-title":"Effects of overexpressing FoxO1 on apoptosis in glomeruli of diabetic mice and in podocytes cultured in high glucose medium","volume":"478","author":"Li","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.ijbiomac.2017.03.124","article-title":"Bamboo leaf extract ameliorates diabetic nephropathy through activating the AKT signaling pathway in rats","volume":"105","author":"Ying","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_53","first-page":"835","article-title":"ROS induces epithelial-mesenchymal transition via the TGF-beta1\/PI3K\/Akt\/mTOR pathway in diabetic nephropathy","volume":"17","author":"Lu","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"117277","DOI":"10.1016\/j.lfs.2020.117277","article-title":"Berberine mitigates high glucose-induced podocyte apoptosis by modulating autophagy via the mTOR\/P70S6K\/4EBP1 pathway","volume":"243","author":"Li","year":"2020","journal-title":"Life Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"850","DOI":"10.2337\/db09-1342","article-title":"The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy","volume":"59","author":"Jiang","year":"2010","journal-title":"Diabetes"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.2337\/db11-0807","article-title":"Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy","volume":"60","author":"Zheng","year":"2011","journal-title":"Diabetes"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/13813455.2021.1890129","article-title":"Kaempferol attenuates diabetic nephropathy in streptozotocin-induced diabetic rats by a hypoglycaemic effect and concomitant activation of the Nrf-2\/Ho-1\/antioxidants axis","volume":"129","author":"Alshehri","year":"2023","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","article-title":"Sodium-glucose cotransporter 2 inhibition suppresses HIF-1alpha-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice","volume":"11","author":"Cai","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1681\/ASN.2011010026","article-title":"AMPK mediates the initiation of kidney disease induced by a high-fat diet","volume":"22","author":"Decleves","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes","volume":"68","author":"Graaf","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1160\/TH16-07-0586","article-title":"Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation","volume":"117","author":"Barale","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.2337\/db19-0204","article-title":"Comparison of Kidney Transcriptomic Profiles of Early and Advanced Diabetic Nephropathy Reveals Potential New Mechanisms for Disease Progression","volume":"68","author":"Fan","year":"2019","journal-title":"Diabetes"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-010-2028-x","article-title":"Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes","volume":"54","author":"Kodera","year":"2011","journal-title":"Diabetologia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: A mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"754239","DOI":"10.3389\/fphar.2021.754239","article-title":"Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease","volume":"12","author":"Kawanami","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: Pathophysiological basis","volume":"96","author":"Girerd","year":"2019","journal-title":"Kidney Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1159\/000355736","article-title":"Eplerenone-mediated aldosterone blockade prevents renal fibrosis by reducing renal inflammation, interstitial cell proliferation and oxidative stress","volume":"37","author":"Chen","year":"2013","journal-title":"Kidney Blood Press. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/wsbm.69","article-title":"Oxygen homeostasis","volume":"2","author":"Semenza","year":"2010","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/MNH.0000000000000527","article-title":"Cullin-Ring ubiquitin ligases in kidney health and disease","volume":"28","author":"Cornelius","year":"2019","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev.biochem.74.082803.133142","article-title":"Proline hydroxylation and gene expression","volume":"74","author":"Kaelin","year":"2005","journal-title":"Annu. Rev. Biochem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"42719","DOI":"10.1074\/jbc.M406713200","article-title":"Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (FIH) in regulating hypoxia-inducible factor (HIF) transcriptional target genes [corrected]","volume":"279","author":"Stolze","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/01.ASN.0000018408.51388.57","article-title":"Peritubular capillary regression during the progression of experimental obstructive nephropathy","volume":"13","author":"Ohashi","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/archinte.162.12.1401","article-title":"Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988\u20131994)","volume":"162","author":"Astor","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphys.2017.00099","article-title":"Renal Hypoxia in CKD. Pathophysiology and Detecting Methods","volume":"8","author":"Hirakawa","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"Korner","year":"1994","journal-title":"Diabetes"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1097\/01.ASN.0000019781.90630.0F","article-title":"Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats","volume":"13","author":"Adler","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Shu, S., Wang, Y., Zheng, M., Liu, Z., Cai, J., Tang, C., and Dong, Z. (2019). Hypoxia and Hypoxia-Inducible Factors in Kidney Injury and Repair. Cells, 8.","DOI":"10.3390\/cells8030207"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"eabh2169","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1042\/CS20210061","article-title":"Effects of HIF-1alpha on renal fibrosis in cisplatin-induced chronic kidney disease","volume":"135","author":"Zhao","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"927329","DOI":"10.3389\/fendo.2022.927329","article-title":"Molecular mechanisms underlying the role of hypoxia-inducible factor-1 alpha in metabolic reprogramming in renal fibrosis","volume":"13","author":"Wei","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41420-021-00443-x","article-title":"SIRT1 attenuates renal fibrosis by repressing HIF-2alpha","volume":"7","author":"Li","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5483\/BMBRep.2022-0145","article-title":"Effects of long-term tubular HIF-2alpha overexpression on progressive renal fibrosis in a chronic kidney disease model","volume":"56","author":"Kim","year":"2023","journal-title":"BMB Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"788977","DOI":"10.3389\/fphar.2021.788977","article-title":"Roxadustat (FG-4592) Facilitates Recovery from Renal Damage by Ameliorating Mitochondrial Dysfunction Induced by Folic Acid","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/0886022X.2011.653754","article-title":"Perspective in chronic kidney disease: Targeting hypoxia-inducible factor (HIF) as potential therapeutic approach","volume":"34","author":"Deshmukh","year":"2012","journal-title":"Ren. Fail."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"Fasching","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"C951","DOI":"10.1152\/ajpcell.00528.2022","article-title":"Renoprotective effects of empagliflozin are linked to activation of the tubuloglomerular feedback mechanism and blunting of the complement system","volume":"324","author":"Chen","year":"2023","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/ndt\/gfaa234","article-title":"The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics","volume":"35","author":"Wheeler","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_99","unstructured":"The Nuffield Department of Population Health Renal Studies Group, and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium (2022). Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials. Lancet, 400, 1788\u20131801."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"20420188221112490","DOI":"10.1177\/20420188221112490","article-title":"The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: From randomised trials to clinical practice","volume":"13","author":"Kreiner","year":"2022","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/ckj\/sfac069","article-title":"GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: State of the art","volume":"15","author":"Granata","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/ndt\/gfad009","article-title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"38","author":"Rossing","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_106","unstructured":"Novo Nordisk (2023, October 10). Novo Nordisk Will Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, FLOW, Based on Interim Analysis. Available online: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=166327."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/HYPERTENSIONAHA.107.098012","article-title":"Mineralocorticoid receptor activation and oxidative stress","volume":"50","author":"Funder","year":"2007","journal-title":"Hypertension"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.steroids.2014.04.005","article-title":"Mineralocorticoid receptors in immune cells: Emerging role in cardiovascular disease","volume":"91","author":"Bene","year":"2014","journal-title":"Steroids"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"J. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1093\/ndt\/gfg339","article-title":"Aldosterone receptor blockade and the role of eplerenone: Evolving perspectives","volume":"18","author":"Epstein","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S2213-8587(14)70194-9","article-title":"Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: A double-blind, randomised, placebo-controlled trial","volume":"2","author":"Ando","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/ndt\/gfac322","article-title":"Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease","volume":"38","author":"Lo","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014Mechanistic and therapeutic effects","volume":"18","author":"Bakris","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000527835","article-title":"Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia","volume":"9","author":"Li","year":"2023","journal-title":"Kidney Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","article-title":"Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, open-label, active-controlled study (DOLOMITES)","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jacbts.2020.05.006","article-title":"Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders","volume":"5","author":"Packer","year":"2020","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A Phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/1\/137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:47:17Z","timestamp":1760104037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/1\/137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["biom14010137"],"URL":"https:\/\/doi.org\/10.3390\/biom14010137","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]}}}